Vaccine Therapy for the Management of Penile Cancer: Evidence, Opportunities and Challenges
Vaccines · 06.07.2026 · 14 (7) · 597
DOI: 10.3390/vaccines14070597 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 06.07.2026. Verfasst von Firas Hatoum und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genitourinary Oncology and Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Penile squamous cell carcinoma (PSCC) is a rare malignancy with limited therapeutic options in advanced and recurrent diseases. Advanced PSCC is typically managed with multimodal therapy, including neoadjuvant chemotherapy or chemoradiation followed by surgery; however, durable responses remain uncommon, and outcomes after recurrence are poor. Cancer vaccines represent a promising immunotherapeutic strategy, as these treatments induce tumor-specific immunity and heightened immune surveillance against penile cancer cells. While therapeutic cancer vaccines have not yet demonstrated consistent clinical efficacy as monotherapy in PSCC, their integration with complementary immune-modulating approaches, particularly immune checkpoint blockade, represents a rational strategy to enhance antitumor immunity. This review summarizes the rationale for vaccine development in PSCC, with emphasis on HPV-derived antigens, neoantigens, and emerging tumor-associated targets. We examine major vaccine platforms, including viral-vector, peptide-based, nucleic acid, and dendritic cell-based approaches. We also discuss how spatial transcriptomics, single-cell RNA sequencing, artificial intelligence-assisted antigen prediction, and nanotechnology-enhanced delivery systems may support future personalized vaccine development. Overall, therapeutic vaccines remain investigational in PSCC but may become relevant within biomarker-driven, combination-based immunotherapy strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genitourinary Oncology and Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
- Department of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA.
- Department of Genitourinary Oncology, Orlando Health Cancer Institute, Orlando, FL 32806, USA.
ORCID-Profile: Firas Hatoum, Ricardo Nehme, Philippe E Spiess
Zitieren
APA
Hatoum, F., Nehme, R., Fazili, A., Miller, J., Johnson, J. S., Le, C., Spiess, P. E., & Chahoud, J. (2026). Vaccine Therapy for the Management of Penile Cancer: Evidence, Opportunities and Challenges. Vaccines, 14(7), 597. https://doi.org/10.3390/vaccines14070597
Vancouver
Hatoum F, Nehme R, Fazili A, Miller J, Johnson JS, Le C, et al. Vaccine Therapy for the Management of Penile Cancer: Evidence, Opportunities and Challenges. Vaccines. 2026;14(7):597. doi:10.3390/vaccines14070597
BibTeX
@article{Hatoum2026,
author = {Hatoum, Firas and Nehme, Ricardo and Fazili, Adnan and Miller, Justin and Johnson, Jeffrey S and Le, Casey and Spiess, Philippe E and Chahoud, Jad},
title = {Vaccine Therapy for the Management of Penile Cancer: Evidence, Opportunities and Challenges},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {7},
pages = {597},
doi = {10.3390/vaccines14070597}
}
EUVIMED